In this issue:
Improved risk prediction calculator for SN positivity in patients with melanoma
Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response
Anti-PD1 checkpoint inhibitor therapy in acral melanoma
T-cell receptor diversity as a prognostic biomarker in melanoma patients
Outcomes after progression with anti-PD-1/PD-L1 therapy for advanced melanoma
Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases
Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy
Diagnostic performance of a deep learning convolutional neural network in the differentiation of combined naevi and melanomas
Vitiligo expansion and correlation with durable response to anti-PD-1 for advanced melanoma
Adjuvant therapy with PEG-IFNα-2b vs observation in stage II B/C patients with ulcerated primary
Please login below to download this issue (PDF)